Medicine Matters oncology
Medicine Matters oncology
Enriched treatment pathway for non-driver NSCLC
Enriched treatment pathway for non-driver NSCLC

Access our new interactive and instructional tool, designed to help you navigate the different treatment lines of non-driver NSCLC.

It is targeted at international (medical and radiation) oncologists and any other healthcare professionals involved in the diagnosis, treatment, and follow-up of patients with lung cancer.

Select your region:

Launch the North American Pathway

Join Dr Mark Socinski as he guides you through this independent educational pathway for North American practice, providing expert insight and analysis to aid your own clinical decision making.

The pathway tool will enable you to:

  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
Launch the European Pathway

Join Dr Enriqueta Felip (Vall d’Hebron Hospital, Barcelona, Spain) and Dr David Heigener (Helios Klinik Schleswig, Germany) as they guide you through this independent educational pathway for European practice, providing expert insight and analysis to aid your own clinical decision making.

The pathway tool will enable you to:

  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
Dr Enriqueta Felip (left) and Dr David Heigener (right)
Launch the Asian Pathway

Join Dr Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Korea) as she guides you through this independent educational pathway for Asian practice, providing expert insight and analysis to aid your own clinical decision making.

The pathway tool will enable you to:

  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape

Background

In a time of rapid advances and ever expanding treatment options, it is becoming increasingly difficult to keep up to date with all the evidence-based recommendations, trial data, and emerging therapies.

This tool has been designed to help navigate the different treatment lines of non-driver NSCLC, enhanced by leading expert opinion, learning resources, and relevant data summaries.

Educational grant

This activity is supported by an education grant from Eli Lilly and Company.

Further resources

Expert videos and a scientific summary titled: Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations are also available here.